11 Deaths Prompt EU Review Of Novartis Drug Gilenya
A European regulator said Friday it was probing Novartis AG's Gilenya after learning that 11 patients who took the multiple sclerosis drug had died, while other Gilenya users reported experiencing heart...To view the full article, register now.
Already a subscriber? Click here to view full article